Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell
冻干仿生人造红细胞的快速重建
基本信息
- 批准号:10010242
- 负责人:
- 金额:$ 37.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffinityAlbuminsAmericanAuthorization documentationBenignBloodBlood PressureBlood SubstitutesCaringCell physiologyCharacteristicsClinical Trials DesignCollaborationsColloidsComplexCountryDepartment of DefenseDevelopmentEnvironmentErythrocytesEventFreeze DryingFundingGoalsGrantHemoglobinHemorrhageHemorrhagic ShockHome environmentHospitalsHumanImmune responseIndividualIndustryIntellectual PropertyLactated Ringer&aposs SolutionLifeLiquid substanceLungNitric OxideNormal salineOsmolalitiesOsmolar ConcentrationOxygenPatientsPhasePhysiologicalPlasmaPlasmalyte APre-hospitalization careProcessProductionPublishingRed CrossResearchResourcesResuscitationRiskSecureSmall Business Innovation Research GrantSolidSterilityTestingTherapeuticTimeTissuesTrainingTransfusionTranslatingTraumaVascular blood supplyWaterWhole Bloodbaseblood productcost effectivecrystalloiddesignexpectationexperiencehuman studyin vivoinnovationmass casualtynanoencapsulatedoperationpreclinical developmentpressurepreventpreventable deathprototyperapid techniquereconstitutiontransfusion medicinevasoconstriction
项目摘要
PROJECT SUMMARY
There is need for an artificial oxygen (O2) carrier to substitute for stored blood products, which at times are
unavailable (pre-hospital care, austere environments, resource-limited countries), undesirable (risk of immune
response), or in short supply to meet demand (mass casualty event). Moreover, transfusion of a crystalloid or
colloid solution alone will lead to dilutional deficiencies of blood components such as red blood cells (RBCs),
which are critical for delivering oxygen (O2) to the various tissues. KaloCyte's focus is to develop ErythroMer
(EM), a lyophilized, bio-inspired, artificial RBC, which will transform how patients who need a transfusion are
treated when stored RBCs or whole blood are not an option. Previous oxygen carrier products have had two
major design flaws preventing them from mimicking RBC physiology: (1) inability to appropriately release O2 to
tissues after capture in the lungs and (2) sequestration of nitric oxide (NO) resulting in vasoconstriction. EM is
designed to not only carry O2 but also surmount the barriers encountered by prior oxygen carriers (intended as
red blood cell substitutes). EM accomplishes this by emulating physiologic RBC O2 capture and delivery along
with benign interaction with the vasculature. These key bio-inspired design features differentiate EM from
previous attempts. Moreover, EM is designed for sterile lyophilization and so, is amenable to facile, rapid
reconstitution after extended dry storage under ambient conditions. EM offers a pragmatic approach to a complex
need and is designed for cost-effective production at scale. Our prototype has passed rigorous initial ex vivo and
in vivo “proof of concept” testing. KaloCyte was founded so that we may translate EM innovations into a
pragmatic therapeutic and as well as realize the commercial potential of a disruptive introduction into transfusion
medicine. Our project goals are to enable rapid, facile reconstitution and establish the optimal colloid (albumin
and freeze-dried plasma), and crystalloid (normal saline, lactated ringers, PlasmaLyte A) ratios for EM
resuspension, while not disrupting the osmolality and oncotic pressure of blood. EM intellectual property is robust
and secured by KaloCyte, which is supported by a solid research team, our CEO with a strong therapeutic
industry background and scientific advisors, with experience in hemoglobin-based oxygen carrier development,
lyophilization, transfusion medicine, hemorrhage & resuscitation, pre-clinical development and trial design. SBIR
funding will enable KaloCyte to critical pre-clinical development in EM production and initiate groundwork
required for IND authorization. Of note, our initial studies and the approach herein meet published FDA
expectations for blood substitutes. Given the significant need and market potential we have hemorrhagic shock
as the first indication for FDA approval. Following a successful trial for hemorrhagic shock, we would expand EM
into other settings and exploit the design to extend efficacies beyond that of stored blood.
项目摘要
需要人工氧(O2)载体来替代储存的血液制品,所述血液制品有时被
不可用(院前护理、严峻的环境、资源有限的国家)、不受欢迎(免疫风险
反应),或供应短缺,以满足需求(大规模伤亡事件)。此外,输注晶体或
单独的胶体溶液将导致血液成分如红细胞(RBC)的稀释不足,
这对于将氧气(O2)输送到各种组织是至关重要的。KaloCyte的重点是开发ErythroMer
(EM)这是一种冻干的、生物激发的人造红细胞,它将改变需要输血的患者的生活方式。
当储存的红细胞或全血不是一种选择时进行治疗。以前的氧载体产品有两个
主要的设计缺陷阻止它们模仿RBC生理学:(1)不能适当地释放O2,
在肺中捕获后的组织和(2)一氧化氮(NO)的隔离导致血管收缩。EM是
设计成不仅携带O2,而且克服现有氧载体(旨在作为
红细胞替代品)。EM通过模拟生理RBC O2捕获和输送沿着
与血管系统良性互动这些关键的生物灵感设计特征使EM与
以前的尝试。此外,EM被设计用于无菌冻干,因此,适合于方便、快速地冻干。
在环境条件下延长干燥储存后进行复溶。EM提供了一种务实的方法,
需要,并设计用于大规模的成本效益生产。我们的原型已经通过了严格的初始体外试验,
体内“概念验证”测试。KaloCyte的成立是为了将EM创新转化为
务实的治疗方法,并实现颠覆性引入输血的商业潜力
药我们的项目目标是使快速,简便的重建和建立最佳的胶体(白蛋白
和冻干血浆)和晶体(生理盐水、乳酸林格氏液、PlasmaLyte A)比率
重悬,同时不破坏血液的渗透压和渗透压。EM知识产权是强大的
并由KaloCyte担保,这是由一个坚实的研究团队支持,我们的首席执行官与强大的治疗
行业背景和科学顾问,具有血红蛋白氧载体开发经验,
冻干、输血药物、出血和复苏、临床前开发和试验设计。SBIR
资金将使KaloCyte能够在EM生产中进行关键的临床前开发,并启动基础工作
需要IND授权。值得注意的是,我们的初步研究和本文中的方法符合FDA公布的标准。
对血液替代品的期望考虑到巨大的需求和市场潜力,
作为FDA批准的第一个适应症。在失血性休克试验成功后,我们将扩大EM
并利用该设计将功效扩展到储存血液之外。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Esma Alp其他文献
Esma Alp的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Esma Alp', 18)}}的其他基金
Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute)
ErythroMer(红细胞替代品)的关键前体 KC1003 的生产放大、纯化和分析方法开发、验证和鉴定
- 批准号:
10324723 - 财政年份:2017
- 资助金额:
$ 37.32万 - 项目类别:
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
ErythroMer:纳米级生物合成红细胞替代品
- 批准号:
10581181 - 财政年份:2017
- 资助金额:
$ 37.32万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 37.32万 - 项目类别:
Studentship